Product Information
TADALAFIL 2.5 MG TABLET is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.1127 per EA under NDC 62332017715. Its NADAC has been published 389 times since Apr 24, 2019.
FDA first approved this application on Mar 26, 2019. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332017715
Classification
Generic
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TADALAFILApproval Type
Generic (ANDA)
FDA Application
ANDA204809FDA Approved
3/26/2019
TE Code
AB1
On Market Since
3/26/2019
Pharmacological Classes
Price Statistics
The NADAC for TADALAFIL 2.5 MG TABLET has been published 389 times since Apr 24, 2019, and over the history we have for it it has declined 98.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1127 per EA |
|---|---|
| All-time high | $7.6664 (Jun 12, 2019) |
| All-time low | $0.0828 (Jul 17, 2024) |
| 52-week high | $0.1262 |
| 52-week low | $0.1127 |
| Median price | $0.1697 |
| Average price | $0.3375 |
| Largest weekly change | -96.2% (Jun 19, 2019) |
| Weeks tracked | 389 |
| Tracking since | Apr 24, 2019 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tadalafil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 5 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TADALAFIL 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TADALAFIL 2.5 MG TABLET, manufactured by Alembic Pharmaceuticals Inc., is $0.1127 per EA (NDC 62332017715), effective Sep 30, 2026.
How has the price of TADALAFIL 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for TADALAFIL 2.5 MG TABLET has declined 98.5%. It has been tracked across 389 weekly CMS publications since Apr 24, 2019.
What are the highest and lowest recorded NADAC prices for TADALAFIL 2.5 MG TABLET?
Since Apr 24, 2019, the NADAC for TADALAFIL 2.5 MG TABLET has ranged from a low of $0.0828 (Jul 17, 2024) to a high of $7.6664 (Jun 12, 2019), with a median of $0.1697 per EA.
Are there cheaper alternatives to TADALAFIL 2.5 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TADALAFIL 2.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TADALAFIL 2.5 MG TABLET?
TADALAFIL 2.5 MG TABLET (NDC 62332017715) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.